F-star Therapeutics

Our acquisition

F-star Therapeutics

Our acquisition

F-star Therapeutics


Founded in 2006, F-star is a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and have improved lives. F-star is committed to working towards a future free from cancer and other serious diseases, through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments.

F-star has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.

Science Platform

The novel platform of tetravalent mAb2 bispecific antibodies has a natural human antibody format. This allows for a straightforward manufacturing process and may provide a favorable safety profile and strong biological potency. Multiple clinical trials are underway.

F-star product candidates are designed to simultaneously address multiple immune-evasion pathways that limit the effectiveness of existing therapies. These are potentially first- and best-in-class drug candidates for patients with cancer who have few other options.

F-star has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising immuno-oncology targets in drug development, including LAG-3 and CD137

F-star Team

F-star has a fantastic team of scientists, researchers, and other specialists working together to develop next-generation immunotherapies.

Acquisition

On 9th March 2023, following regulatory approvals, invoX announced that it has completed the acquisition of F-star Therapeutics.